
New Proposals and Legislation Strengthen Europe’s Position in the Pharmaceutical Arena
Key Takeaways
- A proposed EU Public Procurement Act would harmonize procurement rules, advance digitalization, and permit European preference criteria, shifting award decisions toward best price–quality rather than lowest price.
- Political agreement on new pharmaceutical legislation replaces key EU medicines laws, targeting competitiveness, unmet need, shortages, and AMR while introducing new R&D incentives and an implementation transition through 2028.
Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
The European Union (EU) continues to adopt new proposals and legislation to strengthen Europe’s position in the global pharmaceutical arena. In September 2026, the European Commission (EC) adopted a proposal for a Public Procurement Act that would allow preference for European products in public procurement within certain strategic sectors.1 The EU reached a political agreement on the new pharmaceutical legislation that will overhaul the regulatory framework, drive research and development, and improve patient access to innovative medicines. Additionally, the European Medicines Agency (EMA) updated sponsors on the validation and qualification of computerized systems used in clinical trials and revised its good pharmacovigilance practices (GVP) Module III to ensure the long-term safety and mitigate risks to patients. 2,3
European Commission Adopted a Proposal for a Public Procurement Act
On September 8, 2026, the EC adopted a proposal for a Public Procurement Act to replace the EU’s current horizontal with a single, directly applicable regulation. The proposal simplifies rules, advances digitalization, and European preference criteria, and helps public buyers better integrate environmental, social, innovation, security, and resilience considerations. The European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomed the proposal, particularly its use of the Best Price-Quality Ratio as the default award methodology and its focus on quality, innovation, resilience, and security of supply, and sustainability. It supports procurement approaches that recognize pharmaceutical innovation rather than prioritizing the lowest purchase price. However, the EFPIA argued that price-only procurement should be allowed only in clearly defined exceptional circumstances.1
EU reached a political agreement new pharmaceutical legislation
On November 10, 2026, the European Parliament and the Council of the European Union reached a political agreement on the reform of the EU pharmaceutical legislation on December 11, 2025.4 This new pharmaceutical legislation (NPL) replaces several major pieces of legislation, including Regulation (EC) No 726/2004, the Orphan Medicines Regulation (EC) No 141/2000, elements of the Paediatric Medicines Regulation, and Directive 2001/83/EC.5-8The NPL aims to boost the competitiveness and appeal of Europe’s pharmaceutical industry, and foster innovation, especially in areas where medical needs remain unmet. It should improve patient access to medicines across Member States, strengthen the management and prevention of medicine shortages, and tackle antimicrobial resistance (AMR). It offers new incentivises to drive innovative pharmaceutical research and development (Table 1).
The new framework also places greater emphasis on addressing unmet medical needs and improving access across Member States. The following 2 years, through 2028, will serve as a transition period, giving all EU Member States time to update their national laws to align with the new rules. A governance structure has been established to support implementation of the NPL, to ensure a smooth transition, and bring all stakeholders into alignment by 2028.
In November 2026, the EMA hosted a hybrid SME Info Day for small and medium-sized enterprises (SMEs), offering practical guidance and case studies to help the pharmaceutical sector understand how changes to the EU pharmaceutical framework affect medicines development and authorization.9 It also hosted a stakeholder meeting to discuss eligibility criteria for a priority antimicrobial and the conditions for requesting a transferable data exclusivity voucher (TDVE).10 The EC, EMA, and EU Member States will provide implementation guidance to stakeholders over the coming months.
EMA Clinical Trial Applications Advice Pilot Becomes Permanent
In October 2026, the EMA announced that the Accelerating Clinical Trials in the European Union (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative in January 2027.11 The initiative improves applications and clinical trial assessments by strengthening cooperation across Europe’s medicines regulatory network. Coordinated by the Heads of Medicines Agencies (HMA) through its Clinical Trials Coordination Group (CTCG), the advice procedure gives sponsors technical and regulatory support before they submit a clinical trial application through the Clinical Trials Information System (CTIS). Launched in 2024, the pilot helps sponsors improve applications through consolidated feedback from concerned Member States on key pre-submission topics.
Before this pilot, sponsors could receive technical and regulatory support only at the national level, from the Member State responsible for evaluating their application. Making the initiative permanent will ensure that sponsors continue to receive guidance before submitting clinical trial applications through CTIS. ACT EU will manage pilot applications already submitted through 2026. A report on lessons from approximately 30 applications will be published by year-end. Updated sponsor guidance and templates will be available on the CTCG website in January 2027. Making the initiative permanent supports the European Biotech Act by helping sponsors navigate the EU clinical trials framework.
EMA Updates Sponsors on Validation and Qualification of Computerized Systems Used in Clinical Trials
In October 2026, the EMA published its notice to sponsors on the validation and qualification of computerized systems used in clinical trials.2The document clarifies that sponsors are responsible for validation, even when a vendor built and operates the system. Inspectors must be able to review the validation documents, regardless of who performed the work; if a vendor does not permit audits, inspections, or access to specifications, the system should not be used. Time on the market is irrelevant. If a company cannot demonstrate that a system is validated, regulators may not accept the data.
EMA Updates to GVP Module III and Provides Additional Training
In October 2026, the EMA updated sponsors on EU Good Pharmacovigilance Practices (GVP). The revised GVP Module III, “Pharmacovigilance inspections,” took legal effect on September 10, 2026.12 The updates reflected new legal provisions on subcontracting, removed clinical trial content which is governed elsewhere, refreshed fee and reference materials, clarified remote inspection practices, and strengthened the risk-based inspection cycle. By incorporating the new subcontracting provisions and reinforcing the risk-based inspection cycle, the revisions confirm that EU pharmacovigilance inspections extend across the entire contracting chain and, where activities take place outside the EU, across borders.13Work is also progressing on EU-GVP Modules II, IV, V, VI, and XV, as well as the vaccine-specific Considerations Chapter P.I. A new addendum to EU-GVP Module VII is planned to address reporting on the implementation status of risk minimization measures in periodic safety update reports. A broader revision of Module VII will start in 2028 as part of the NPL and public consultations will be staggered over the year ahead.14
On November 9, 2026, the EMA announced that new qualified persons for pharmacovigilance (QPPV) and responsible person users of EudraVigilance (EV) must complete a 5-day online, hands-on course and pass a knowledge test before they get production access. The online training course is mandatory for those using the EV System to submit ISO/ICH E2B(R3) individual case safety reports (ICSRs) in the EU.15The EV is the EU’s system for managing and analyzing information on adverse reactions to medicines authorized or studied in clinical trials in the European Economic Area (EEA). As of August 2026, EudraVigilance contained 18.5 million individual cases, representing more than 32 million case transactions, and received approximately 7400 ICSR transactions per day in 2025.15 On December 1, 2026, the HMA and EMA will hold a multi-stakeholder forum on EV and signal detection to inform stakeholders about ongoing and upcoming developments in international guidance, signal management updates, and the use of real-world evidence.16
Future Outlook of EU Regulation on the Pharma Industry
The NPL should provide the clarity and predictability needed to sustain investment in Europe’s pharmaceutical industry. This framework supports EU competitiveness and innovation and creates a stable investment environment.17 In addition, streamlining clinical trial applications and improving pharmacovigilance processes should make Europe more attractive for conducting clinical trials and speed up patient access to safe and innovative medicines. To remain competitive, pharma and biotech companies must keep abreast of regulatory changes and prepare for them, as the EMA will continue to update its guidance over the year ahead.
References
- EFPIA supports progress towards public procurement that rewards quality and innovation. News release. European Federation of Pharmaceutical Industries and Associations September 9, 2026. Accessed November 11, 2026.
https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/efpia-supports-progress-towards-public-procurement-that-rewards-quality-and-innovation/ - Notice to sponsors on validation and qualification of computerized systems used in clinical trials. News release. European Medicines Agency. October 29, 2026. Accessed November 11, 2026.
https://www.ema.europa.eu/system/files/documents/regulatory-procedural-guideline/notice-sponsors_computerised-systems-clinical-trials_rev1-en.pdf - Bahri P. Update on the EU-Good Pharmacovigilance Practices (EU-GVP) 21st EMA Industry Stakeholder Platform Operation of EU Pharmacovigilance. European Medicines Agency. October 20, 2026. Accessed November 11, 2026.
https://www.ema.europa.eu/en/documents/presentation/presentation-update-eu-good-pharmacovigilance-practices-eu-gvp_en.pdf - Reform of the EU pharmaceutical legislation. European Medicines Agency. November 11, 2026. Accessed November 11, 2026.
https://www.ema.europa.eu/en/about-us/what-we-do/reform-eu-pharmaceutical-legislation - Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance).European Medicines Agency. March 31, 2004. Accessed November 11, 2026.
https://eur-lex.europa.eu/eli/reg/2004/726/oj/eng - Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products.European Medicines Agency. December 16, 1999. Accessed November 11, 2026. https://eur-lex.europa.eu/eli/reg/2000/141/oj
- Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance).European Medicines Agency. December 12, 2006. Accessed November 11, 2026. https://eur-lex.europa.eu/eli/reg/2006/1901/oj/eng
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.European Medicines Agency. November 6, 2021.Accessed November 11, 2026. https://eur-lex.europa.eu/eli/dir/2001/83/oj/eng
- SME info day - navigating EMA support: From innovation to marketing authorization.European Medicines Agency. November 6, 2026. Accessed November 11, 2026. https://www.ema.europa.eu/en/events/sme-info-day-navigating-ema-support-innovation-marketing-authorisation
- Transferable data exclusivity voucher for priority antimicrobials in the new pharmaceutical legislation.European Medicines Agency. November 12, 2026. Accessed November 11, 2026.
https://www.ema.europa.eu/en/documents/agenda/agenda-stakeholder-meeting-november-2026_en.pdf - Clinical trial applications advice pilot becomes permanent.European Medicines Agency. October 8, 2026. Accessed November 11, 2026. https://www.ema.europa.eu/en/news/clinical-trial-applications-advice-pilot-becomes-permanent
- Guidelines on good pharmacovigilance practices (GVP). Module III – Pharmacovigilance inspections (Rev 2).European Medicines Agency. September 4, 2026. Accessed November 11, 2026.
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections-rev-2_en.pdf - Fatima M. EMA GVP Module III revision 2: EU pharmacovigilance inspections effective 10 September 2026. MFLRC. September 11, 2026. Accessed November 11, 2026.
https://mflrc.com/article/ema-gvp-module-iii-rev-2-pharmacovigilance-inspections-2026 - Highlights from the 21st EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation 20 October 2026.European Medicines Agency. October 30, 2026. Accessed November 11, 2026. https://www.ema.europa.eu/system/files/documents/report/highlights_21st-ema-industry-platform-meeting-operation-eu-pharmacovigilance_en.pdf
- Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system.European Medicines Agency. November 8-12, 2026. Accessed November 11, 2026.
https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-73 - Agenda - Second HMA/EMA multi-stakeholder forum on EudraVigilance and signal detection. European Medicines Agency. December 1, 2026. Accessed November 11, 2026. https://www.ema.europa.eu/en/documents/agenda/agenda-second-hma-ema-multi-stakeholder-forum-eudravigilance-signal-detection_en.pdf
- Meulenbelt M. The EU Overhauls Pharma Laws What You Need To Know. Outsourced Pharma. November 2, 2026.Accessed November 11, 2026.
https://www.outsourcedpharma.com/doc/the-eu-overhauls-pharma-laws-what-you-need-to-know-0001
Related to this article









